• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Aradigm Corp. is a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. Aradigm was founded in 1991 and is headquartered in Hayward, CA.
| Market Cap | 684.891 Thousand | Shares Outstanding | 15.22 Million | Avg 30-day Volume | 21.852 Thousand |
| P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.81 |
| Price to Revenue | 3.9613 | Debt to Equity | -0.0427 | EBITDA | -10.255 Million |
| Price to Book Value | 0.0 | Operating Margin | -279.8402 | Enterprise Value | 15.408 Million |
| Current Ratio | 1.232 | EPS Growth | -0.112 | Quick Ratio | 1.086 |
| 1 Yr BETA | 1.0751 | 52-week High/Low | 0.0 / | Profit Margin | -374.7945 |
| Operating Cash Flow Growth | 5.7632 | Free Cash Flow to Firm (FCFF) TTM | -10.842 Million | Free Cash Flow to Equity (FCFE) TTM | -1.491 Million |
| Altman Z-Score | -183.1343 |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
4,279,681 | 2019-09-02 | 0 | |
|
No longer subject to file | 2019-09-01 | 0 | |
|
FIRST EAGLE INVESTMENT MANAGEMENT, LLC |
|
0 | 2019-05-01 | 0 |
|
FROEHLICH JUERGEN KURT CHIEF MEDICAL OFFICER |
|
151,485 | 2018-10-26 | 0 |
|
0 | 2018-06-29 | 0 | |
|
0 | 2018-06-29 | 0 | |
|
0 | 2018-06-29 | 0 | |
|
0 | 2018-06-29 | 0 | |
|
SIEBERT JOHN M INTERIM PRINCIPAL EXEC OFCR |
|
0 | 2018-03-22 | 0 |
|
GONDA IGOR CHIEF EXECUTIVE OFFICER |
|
0 | 2017-12-06 | 0 |
|
PECOTA NANCY E VP AND CFO |
|
0 | 2017-12-06 | 0 |
|
229,724,558 | 2016-04-21 | 0 | |
|
0 | 2016-04-21 | 0 | |
|
FIRST EAGLE INVESTMENT MANAGEMENT, LLC |
|
154,326,899 | 2013-08-27 | 0 |
|
0 | 2013-08-27 | 0 | |
|
0 | 2013-08-27 | 0 | |
|
941,645 | 2013-05-22 | 0 | |
|
80,000 | 2013-05-22 | 0 | |
|
109,030,649 | 2013-05-20 | 0 | |
|
132,331 | 2012-05-25 | 0 | |
|
7,473,328 | 2012-01-01 | 0 | |
|
0 | 2012-01-01 | 0 | |
|
71,357,909 | 2011-07-07 | 0 | |
|
2,098,800 | 2010-12-31 | 0 | |
|
26,204,122 | 2010-11-05 | 0 | |
|
60,732,909 | 2010-09-21 | 0 | |
|
57,516,146 | 2009-12-09 | 0 | |
|
GRIMES D JEFFERY VP LEGAL AFFAIRS, SECRETARY |
|
344,662 | 2009-10-14 | 0 |
|
No longer subject to file | 2008-10-29 | 0 | |
|
5,947,000 | 2008-10-21 | 0 | |
|
240,000 | 2008-07-01 | 0 | |
|
OTULANA BABTUNDE A VP OF CLINCAL AFFAIRS |
|
250,000 | 2007-12-04 | 0 |
|
HALLEEN NORMAN CHIEF FINANCIAL OFFICER |
|
0 | 2007-07-03 | 0 |
|
20,000 | 2007-06-20 | 0 | |
|
6,444,010 | 2007-03-01 | 0 | |
|
89,010 | 2007-03-01 | 0 | |
|
6,355,000 | 2007-01-24 | 0 | |
|
CHESTERMAN THOMAS C SENIOR VP AND CFO |
|
300,000 | 2006-06-27 | 0 |
|
RIGBY JONATHAN VP, BUSINESS DEVELOPMENT |
|
40,000 | 2006-04-12 | 0 |
|
VENKATADRI BOBBA SR. VP OPERATIONS |
|
40,000 | 2006-03-07 | 0 |
|
FARR STEPHEN J SR. VP, CSO |
|
60,000 | 2006-03-07 | 0 |
|
LAWLIS V BRYAN PRESIDENT |
|
150,000 | 2006-03-07 | 0 |
|
TURANIN JOHN J VP, CORPORATE PLANNING AND MGT |
|
40,000 | 2006-03-07 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
